Amethyst Deceiver

Metadata

Regulatory Status

Europe

• Edible wild mushroom in European foraging traditions, though generally not considered a “choice” edible due to small size and thin flesh. Consumed primarily by experienced foragers.
• No medicinal registration in any European jurisdiction. No HMPC, ESCOP, or Commission E monograph.
• Arsenic safety concern: Multiple European studies have documented high arsenic concentrations, leading some food safety authorities to advise caution. A Spanish study found arsenic concentrations of concern in Galician specimens.
• Name “deceiver” refers to the tendency of the mushroom to fade in color as it ages, making identification difficult — the Latin amethystina refers to its vivid purple color when fresh.

United States

• Not commercially marketed as food or supplement. Not assessed by the FDA.
• No GRAS determination.
• Foraged by wild mushroom enthusiasts in eastern North America.

China / Asia

• Not listed in the Chinese Pharmacopoeia. Not used in traditional Chinese medicine.
• Yunnan studies: Research from Yunnan province (SW China) has specifically investigated arsenic concentrations in Laccaria mushrooms, identifying health risks associated with consumption.

Conditions & Indications

Primary: Immune Modulation (Theoretical/Inferred)

• Beta-glucan content: Like most basidiomycete fungi, L. amethystina contains cell wall polysaccharides including beta-glucans and chitin. These compounds are well-established immunomodulators across the fungal kingdom, stimulating innate immune function through Dectin-1, complement receptor 3 (CR3), and TLR-2/6 pathways. However, the specific beta-glucan content, structure, and bioactivity of L. amethystina polysaccharides have not been characterized. [UNCERTAIN]
• Gut microbiome interaction: As a source of insoluble fungal fiber (chitin, beta-glucans), dietary consumption of L. amethystina may influence gut microbiota composition, as documented for edible mushrooms generally. No species-specific studies exist. [UNCERTAIN]

Secondary: Nutritional Support (Inferred)

• Micronutrient content: L. amethystina is reported to contain antioxidants, B vitamins, copper, and potassium, consistent with the general nutritional profile of edible agaric mushrooms. Specific nutritional analysis for this species is limited.
• Ergosterol (provitamin D2): Contains ergosterol, which can be converted to vitamin D2 upon UV exposure.

Emerging/Preclinical

• Mycorrhizal biology insights: L. amethystina has been the subject of significant genomic research, particularly through the related species Laccaria bicolor, whose genome was sequenced and published in Nature (2008). The genomic data reveals expanded gene families for cell wall biosynthesis enzymes (chitin synthases and beta-glucan-modifying enzymes), suggesting potentially complex polysaccharide structures. Whether this translates to biomedically relevant polysaccharide activity is unknown. [NEEDS-RESEARCH]
• No anti-inflammatory, anticancer, or antimicrobial studies have been published for L. amethystina. Any therapeutic claims for this species are currently unsupported by evidence.

Mechanism of Action

Primary Mechanisms

1. Fungal polysaccharide immunomodulation (general, not species-specific): Beta-1,3/1,6-glucans from basidiomycete fungi are recognized by pattern recognition receptors on innate immune cells (macrophages, dendritic cells, neutrophils). The Dectin-1 receptor binds beta-1,3-glucans and triggers downstream signaling through Syk kinase, leading to NF-kB activation, cytokine production (TNF-alpha, IL-6, IL-1beta, IL-12), and enhanced phagocytic activity. Complement receptor 3 (CR3) provides an additional recognition pathway. This mechanism is well-established across numerous medicinal mushrooms but has not been specifically demonstrated for L. amethystina. [UNCERTAIN]

2. Chitin and prebiotic fiber effects: Chitin and chitosan derivatives from fungal cell walls can modulate gut microbiota composition and may enhance intestinal barrier function. These effects have been demonstrated for mushroom dietary fiber generally but not for L. amethystina specifically. [UNCERTAIN]

Secondary Mechanisms

• Ergosterol-derived vitamin D2: Ergosterol in the fruiting body can be photoconverted to vitamin D2 by UVB exposure, contributing to immune regulation through the vitamin D receptor (VDR) signaling pathway.
• Phenolic antioxidant activity: Phenolic compounds in the fruiting body may contribute direct free radical scavenging capacity, though the specific phenolic profile of L. amethystina has not been characterized.

Clinical Evidence Summary

No clinical trials, animal studies, or in vitro pharmacological studies have been published specifically for Laccaria amethystina. The research literature for this species focuses almost exclusively on arsenic bioaccumulation, mycorrhizal ecology, and genomic biology.

Key Studies (Arsenic Safety Focus)

Evidence Limitations

• No pharmacological studies exist for this species. All medicinal claims are inferred from general mushroom biology.
• Arsenic bioaccumulation dominates the research literature and represents the most significant finding for this species.
• The arsenic speciation data (predominantly organic arsenic forms like DMA) is somewhat reassuring compared to inorganic arsenic, but total arsenic levels remain extremely high.
• No beta-glucan characterization, immunomodulatory assay, or bioactivity-guided fractionation has been conducted for L. amethystina.
• The “laccarin” polysaccharide name referenced in some popular sources could not be confirmed in the peer-reviewed scientific literature. [UNCERTAIN]
• Genomic insights from L. bicolor provide indirect evidence of complex polysaccharide biosynthesis but do not constitute direct pharmacological evidence.

Safety Profile

General Assessment

The primary safety concern for Laccaria amethystina is its exceptional capacity to bioaccumulate arsenic from soil. Arsenic concentrations in this species can be 100—300 times higher than in fungi generally, with extreme values exceeding 1,400 mg/kg dry weight in contaminated locations. Even in relatively uncontaminated soils, arsenic levels can be elevated. This makes L. amethystina one of the highest arsenic-accumulating organisms known.

Arsenic Bioaccumulation — Critical Safety Issue

• Concentration range: 4—1,420 mg/kg dry weight depending on soil contamination levels. Mean values of ~135 mg/kg dw have been reported.
• Health risk: A single meal of 300 g fresh weight can deliver approximately 4.1 mg of arsenic, exceeding the FAO/WHO recommended weekly intake of inorganic arsenic.
• Arsenic speciation: The majority (68—74%) of arsenic is present as dimethylarsinic acid (DMA), an organic arsenic form that is less toxic than inorganic arsenate/arsenite. However, DMA is classified as “possibly carcinogenic” (IARC Group 2B), and total arsenic levels remain exceptionally high.
• Soil dependence: Arsenic concentration varies dramatically with soil conditions. Mushrooms from industrially contaminated, mining-adjacent, or naturally arsenic-rich soils pose the greatest risk.

Contraindications

• Collection from contaminated soils: Must not be collected near mining sites, industrial areas, or naturally arsenic-rich geological formations.
• Pregnancy, lactation, and children: Arsenic exposure poses particular risks to fetal development, infants, and children.
• Regular consumption: Even from relatively clean soils, frequent consumption is inadvisable due to cumulative arsenic exposure.

Drug Interactions

• No data available for direct drug interactions.
• Arsenic interaction concern: Chronic arsenic exposure can affect liver and kidney function, potentially altering drug metabolism. This is relevant only in the context of regular, high-volume consumption.

Side Effects

• Acute effects: No acute toxicity from the mushroom itself (aside from arsenic content).
• Chronic arsenic exposure: Potential long-term risks include skin lesions, peripheral neuropathy, cardiovascular disease, and increased cancer risk, all associated with chronic arsenic exposure rather than the mushroom per se.

Toxicology

• Arsenic is the primary toxicological concern. The mushroom is not intrinsically toxic; it bioaccumulates arsenic from its environment through its mycorrhizal root associations.
• No other toxins have been identified in L. amethystina.
• Formal toxicological studies (LD50, subchronic) of the mushroom itself have not been conducted.

Clinical Dosage

No Established Medicinal Dosage

No dosage recommendations exist for any medicinal application of Laccaria amethystina. The species has no history of therapeutic use.

Culinary Consumption (Foraging Context)

• Small portions recommended: Given arsenic concerns, consumption should be infrequent and in small quantities (well under 300 g fresh weight per occasion).
• Source matters critically: Only specimens from known, uncontaminated soils should be considered for consumption.
• Preparation: Always cooked; typical European foraging practice is to saute or add to mixed mushroom dishes.

Safety-Based Consumption Limits

• A conservative approach would limit consumption to no more than occasional small servings (50—100 g fresh weight) from verified clean sources, with long intervals between consumption events.
• There is no established safe consumption frequency that accounts for arsenic bioaccumulation.

Sources

• Zhang J, Li T, Yang YL, et al. Arsenic concentrations and associated health risks in Laccaria mushrooms from Yunnan (SW China). Biol Trace Elem Res. 2015;164(2):261-266
• Koch I, Dee J, House K, et al. Speciation and health risk considerations of arsenic in the edible mushroom Laccaria amethystina collected from contaminated and uncontaminated locations. Appl Geochem. 2013;36:138-144
• Braeuer S, Borovicka J, Goessler W. A unique arsenic speciation profile in Elaphomyces spp. (“deer truffles”)-trimethylarsine oxide and methylarsonous acid as significant arsenic compounds. Anal Bioanal Chem. 2018;410(9):2283-2290
• Garcia MA, Alonso J, Melgar MJ. Total contents of arsenic and associated health risks in edible mushrooms, mushroom supplements and growth substrates from Galicia (NW Spain). Food Chem Toxicol. 2015;73:44-50
• Martin F, Aerts A, Ahren D, et al. The genome of Laccaria bicolor provides insights into mycorrhizal symbiosis. Nature. 2008;452(7183):88-92
• Stijve T, de Meijer AAR. Arsenic accumulation in the mushroom Laccaria amethystina. Chemosphere. 1983;12(7):913-915
• Zombiemyco. Amethyst Deceiver (Laccaria amethystina). Available at: zombiemyco.com
• Shroomer. The Complete Guide to Laccaria Amethystina. Available at: shroomer.com

Connections

• Foraging safety context: L. amethystina is foraged alongside other wild edible mushrooms such as Cantharellus cibarius (chanterelle), Lepista nuda (wood blewit), and Boletus edulis (porcini). Among these commonly foraged species, L. amethystina stands out for its arsenic bioaccumulation risk, which is not shared by the others. Foragers should be aware of this distinctive hazard.
• Immune modulation comparison: The theoretical beta-glucan immunomodulatory potential of L. amethystina is vastly less supported than that of dedicated medicinal species such as Turkey Tail (Trametes versicolor) and Reishi (Ganoderma lucidum), which have extensive clinical evidence for immune modulation. For immune support purposes, these well-studied species are strongly preferred.
• Mycorrhizal mushroom research: As a mycorrhizal species, L. amethystina cannot be easily cultivated like saprotrophic medicinal mushrooms. This limits commercial development and standardization, similar to the challenges faced with Cantharellus cibarius and Boletus edulis.
• Heavy metal accumulation in fungi: The arsenic bioaccumulation of L. amethystina is an extreme example of a broader phenomenon. Many fungi bioaccumulate heavy metals, and source verification is important for all wild-harvested medicinal and edible species.